BioCardia (NASDAQ:BCDA – Get Free Report) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect BioCardia to post earnings of ($0.15) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
BioCardia (NASDAQ:BCDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. On average, analysts expect BioCardia to post ($0.71) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.
BioCardia Stock Performance
NASDAQ:BCDA opened at $0.90 on Tuesday. BioCardia has a fifty-two week low of $0.75 and a fifty-two week high of $1.80. The firm has a market cap of $13.67 million, a PE ratio of -1.41 and a beta of 0.69. The business has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.07.
Analysts Set New Price Targets
View Our Latest Report on BioCardia
BioCardia Company Profile
BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy.
BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.
Further Reading
- Five stocks we like better than BioCardia
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
